U.S. drug developer Novavax Inc said on Tuesday it was doubling its potential COVID-19 vaccine manufacturing capacity to two billion doses annually under an agreement with Serum Institute of India, sending its shares up about 7%.
In August, Novavax signed a deal with Serum Institute, the world’s largest producer of vaccines, to produce a minimum of one billion doses of its vaccine candidate, when approved, for low- and middle-income countries and India.
Novavax’s vaccine is currently in mid-stage trials after an early-stage study showed it produced high levels of antibodies against the novel coronavirus. The company plans to begin late-stage trials in the third quarter. The company is also preparing to deliver 100 million doses to the United States by January after it was awarded $1.6 billion for its potential vaccine, and has also signed supply agreements with Canada and Japan.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Valneva to supply up to 190 million doses of COVID-19 vaccine to UKFrench vaccine maker Valneva said on Monday it would supply the UK with up to 190 million doses of its coronavirus vaccine candidate, VLA2001, over a five-year period.
Read more »
Covid-19 and the Rise of the #ChloeTingChallenge'If you weren't facing eviction, job loss, childcare, family care, structural racism, mental health issues or illness, it felt as if you should be baking, reading literature, and getting toned.' dliebelson writes:
Read more »
Salvation Army gets early start on holiday fundraising campaign to 'rescue Christmas' amid COVID-19 pandemicThe nation's largest social services organization said it will start collecting donations in its iconic red kettles with bell-ringing volunteers Monday instead of waiting until closer to Thanksgiving as in past years.
Read more »
Eli Lilly's rheumatoid arthritis drug helps recovery in COVID-19 patientsEli Lilly and Co said on Monday its rheumatoid arthritis drug baricitinib shortened the time taken to recover from COVID-19 in hospitalized patients when taken in combination with Gilead Sciences Inc's antiviral remdesivir.
Read more »
When will there be a COVID-19 vaccine and should you trust that it's safe?Americans want a COVID-19 vaccine—but worry that it could be rushed out before the election. Here's what the science says.
Read more »
'They're Not Actually Getting Better,' Says Founder Of COVID-19 Long-Haulers Support GroupSurvivor Corps is an online group for COVID-19 long-haulers to document their symptoms, raise money for treatment and research, and provide support. Founder Diana Berrent says she’s seen specialists for many of her complications. | hereandnow
Read more »